美国FDA已经批准Xifaxan(利福昔明片,从柳药品)为在公开的肝性脑病患者复发的危险≥18岁晚期肝病减少550mg。这个批准是基于数据从第三阶段随机,双盲,安慰剂对照,与肝病患者谁曾国审判没有或肝性脑病症状轻微。主要终点,在经历了明显的肝性脑病的突破事件的风险,减少了58个与Xifaxan 550mg%,而治疗的患者与安慰剂(p“0.0001)。关键的次要终点,肝性脑病的经历有关住院,风险降低了50与Xifaxan 550mg%,而治疗的患者与安慰剂(p =0.0129)。 Xifaxan 550mg,预计可于2010年5月底。 Xifaxan已在1片200毫克剂量的力量则显示为旅行者腹泻,由于无创性大肠杆菌的待遇。 The FDA has approved Xifaxan (rifaximin tablets, from Salix Pharmaceuticals) 550mg for the reduction in risk of recurrence of overt hepaticencephalopathy in patients ≥18 years of age with advanced liver disease. This approval is based on data from a Phase 3, randomized, double-blind, placebo-controlled, multinational trialofpatientswithliverdiseasewhohadnoormildsymptomsofhepaticencephalopathy. The primary endpoint, the risk of experiencing a breakthrough overt hepatic encephalopathy episode, was reduced by 58% in patients treated with Xifaxan 550mg compared with placebo (p<0.0001). The key secondary endpoint, risk of experiencing hepatic encephalopathy-related hospitalization, was reduced by 50% in patients treated with Xifaxan 550mg compared with placebo (p=0.0129). Xifaxan 550mg is expected to be available by the end of May 2010. Xifaxan is already available in a 200mg dosage strength tablet indicated for the treatment of traveler's diarrhea due to noninvasive Escherichia coli. 【药品名称】 |
药品通用名 |
剂型 |
规格 |
单位 |
最高零售价格 |
生产企业 | |
GMP |
非GMP | |||||
利福昔明片(欧克双) |
薄膜衣片 |
|
盒 |
15.50 |
|
四川百利药业有限责任公司 |
利福昔明片(欧克双) |
薄膜衣片 |
|
盒 |
20.40 |
|
四川百利药业有限责任公司 |
利福昔明片(欧克双) |
薄膜衣片 |
|
盒 |
25.40 |
|
四川百利药业有限责任公司 |
利福昔明片(欧克双) |
薄膜衣片 |
|
盒 |
30.20 |
|
四川百利药业有限责任公司 |
利福昔明片(欧克双) |
薄膜衣片 |
|
盒 |
39.90 |
|
四川百利药业有限责任公司 |
利福昔明片(欧克双) |
薄膜衣片 |
|
盒 |
49.50 |
|
四川百利药业有限责任公司 |
利福昔明片(昔服申) |
片剂 |
|
盒 |
144.00 |
|
意大利阿尔法韦士曼制药有限公司 |
利福昔明片(莱利青) |
片剂 |
|
盒 |
27.00 |
|
重庆莱美药业股份有限公司 |
利福昔明片(昔服申) |
片剂 |
|
盒 |
50.00 |
|
意大利阿尔伐韦士曼制药公司 |